CV Therapeutics vor Megarally !!!!!!!!!!!!!!! - 500 Beiträge pro Seite

[Masterburger]

Cv Therapeutics hat sich in der schlechten Börsenphase bei 20 € gehalten. Der Kurs zieht die letzten zwei Tage auch wieder an. Heute nach Börsenschluß kommen die Zahlen zum 3 Quartal, deswegen halten sich die Anleger heute auch etwas zurück.

CV Therapeutics to Announce 2002 Third Quarter Financial Results On Thursday, October 17, 2002

PALO ALTO, Calif., Oct. 11 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today announced that it will release third quarter financial results for 2002 after the market closes on Thursday, October 17, 2002. Company management will webcast a conference call at 5:00 p.m. EDT, 2:00 p.m. PDT on the company`s website.

To access the live webcast, please log on to the company`s website at www.cvt.com and go to the Investor Information section. Alternatively, domestic callers may participate in the conference call by dialing [phone], and international callers may participate in the conference call by dialing [phone]. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Tuesday, October 22, 2002. Domestic callers can access the replay by dialing [phone], and international callers can access the replay by dialing [phone], the PIN access number is 6139200.

CV Therapeutics, Inc., headquartered in Palo Alto, CA, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CVT currently has four compounds in clinical trials. Ranolazine, the first in a new class of compounds known as partial fatty acid oxidation (pFOX) inhibitors, is being developed for the potential treatment of chronic angina. Tecadenoson (CVT-510), an A1 adenosine receptor agonist, is being developed for the potential reduction of rapid heart rate during atrial arrhythmias. CVT-3146, an A2A adenosine receptor agonist, is being developed for the potential use as a pharmacologic agent in cardiac perfusion imaging studies. Adentri(TM), an A1 adenosine antagonist, is being developed by our partner Biogen, Inc., for the potential treatment of acute and chronic congestive heart failure. For more information, please visit CV Therapeutics` website at http://www.cvt.com.


Kurshistorie Frankfurt
Datum Erster Hoch Tief Letzter Umsatz
16.10.2002 22,80 22,80 22,00 22,00 150
15.10.2002 21,60 22,80 21,60 22,80 310
14.10.2002 20,50 20,70 20,00 20,70 180
11.10.2002 19,70 20,50 19,70 20,50 300
10.10.2002 19,90 20,30 19,90 20,30 0
09.10.2002 20,40 20,40 20,20 20,20 120
08.10.2002 20,00 20,50 19,90 20,40 524
07.10.2002 20,70 21,10 20,70 21,10 235
04.10.2002 21,00 21,00 20,30 21,00 328
03.10.2002 21,00 21,00 20,70 20,70 30
02.10.2002 22,30 22,30 21,50 21,50 173
01.10.2002 21,10 21,70 21,00 21,50 275
30.09.2002 21,10 21,10 20,30 20,80 650
27.09.2002 21,70 22,00 21,10 21,70 240
26.09.2002 22,00 22,50 22,00 22,50 50
25.09.2002 20,00 21,00 20,00 21,00 60
24.09.2002 19,50 20,25 19,00 20,25 280
23.09.2002 20,20 20,70 19,00 19,90 756
20.09.2002 20,50 21,00 20,00 20,00 245

Cashbestand 470 Mil. $
Marktkap. 550 Mil. $

Strong Buy

[Bundeskanzler_EDMUND]

News!!!

Zahlen von CV!

-0,95 pro Anteil (erwartet 1,18)

Cashbestand ca 420mio$

[Bundeskanzler_EDMUND]

Vorsicht bei CV!!!


Man rechnet bis zum Jahresende weiterhin damit, einen Zulassungsantrag für das Angina Medikament Ranexa bei der US-Gesundheitsbehörde FDA einreichen zu können. Ranexa sei das wohl erste Medikament, dass bei Angina das Herz dazu bringt, für Energie Zucker statt Fett zu verbrennen, was den Krankheitsverlauf lindern könnte, hieß es.

Ein außenstehender Versuchsdurchlauf warnte vor, dass der Pumpintervall der linken Herzkammer durch durch das Medikament verlängert werden könnte. Analysten gehen davon aus, dass diese Nebenwirkung aufgrund der Erhöhung des Risikprofils des Medikamentes zu einer Ablehnung der Marktzulassung durch die FDA führen könnte. Das Unternehmen bekräftigte aber, dass damit alles in Ordnung sei.

[Masterburger]

CVTX
CV Therapeutics, Inc. Nasdaq-NM


Back to Headlines | Previous Story

CV Therapeutics Reports Third Quarter Financial Results

PALO ALTO, Calif., Oct. 17 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today announced a net loss of $24.8 million, or $0.95 per share for the quarter ended September 30, 2002, compared to a net loss of $18.8 million, or $0.85 per share, for the same quarter in 2001. For the nine-months ended September 30, 2002, the Company reported a net loss of $78.4 million, or $3.04 per share, compared to a net loss of $53.3 million, or $2.58 per share, for the same period in 2001.

For the quarter ended September 30, 2002, operating expenses increased to approximately $27.4 million, from $23.8 million for the same quarter in 2001. Total operating expenses increased to $85.9 million for the nine-month period ended September 30, 2002, from $65.4 million for the same period in 2001. The increases in operating expenses for both the quarter and nine-month periods ended September 30, 2002, were primarily due to expenses for the Ranexa(TM) program related to NDA preparation, pre-commercialization activities, and manufacturing-related arrangements.

The Company recognized collaborative research revenue of $1.2 million for the quarter ended September 30, 2002, compared to $2.9 million for the same quarter in 2001. For the nine-month period ended September 30, 2002, the Company recognized revenues of $3.5 million, compared to $5.7 million for the same period in 2001. The revenue recognized for all periods relates to milestone payments earned and the reimbursement of certain development costs from collaborative partners.

At September 30, 2002, the Company had cash, cash equivalents and marketable securities of approximately $420.5 million, compared to $478.4 million at December 31, 2001.

Company management will webcast a conference call on Thursday, October 17, 2002 at 5:00 p.m. EDT, 2:00 p.m. PDT, on the Company`s website. To access the live webcast, please log on to the Company`s website at www.cvt.com and go to the Investor Information section. Alternatively, domestic callers may participate in the conference call by dialing 888-370-6121, and international callers may participate in the conference call by dialing 706-679-7163. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Tuesday, October 22, 2002. Domestic callers can access the replay by dialing 800-642-1687, and international callers can access the replay by dialing 706-645-9291; the PIN access number is 6139200.

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CVT currently has four compounds in clinical trials. Ranexa(TM), the first in a new class of compounds known as partial fatty acid oxidation (pFOX) inhibitors, is being developed for the potential treatment of chronic angina. Tecadenoson (CVT-510), an A1 adenosine receptor agonist, is being developed for the potential reduction of rapid heart rate during atrial arrhythmias. CVT-3146, an A2A adenosine receptor agonist, is being developed for the potential use as a pharmacologic agent in cardiac perfusion imaging studies. Adentri(TM), an A1 adenosine antagonist, is being developed by our partner Biogen, Inc., for the potential treatment of acute and chronic congestive heart failure. For more information, please visit CV Therapeutics` website at http://www.cvt.com .

Except for the historical information contained herein, the matters set forth in this press release, including statements as to development and commercialization of the company`s products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including, the early stage of development; the timing of clinical trials; the dependence on collaborative and licensing agreements; and other risks detailed from time to time in CVT`s SEC reports, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2001. CVT disclaims any intent or obligation to update these forward-looking statements.


CV THERAPEUTICS, INC.
CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)

[Masterburger]

NEEDHAM & CO

CV Therapeutics "strong buy" Datum: 21.10.2002


Rating-Update: Die Analysten vom Investmenthaus Needham & Co stufen die Aktie von CV Therapeutics unverändert mit "strong buy" ein. Das Kursziel sehe man bei 70 US-Dollar. (WKN 912268)




Quelle: AKTIENCHECK.DE AG